Home  »  Companies   »  Amicus Therapeutics Inc. (FOLD) Beta Value: Unders...

Amicus Therapeutics Inc. (FOLD) Beta Value: Understanding the Market Risk

The 36-month beta value for FOLD is also noteworthy at 0.79. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 0 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”

The average price estimated by analysts for FOLD is $15.82, which is $4.09 above than the current price. The public float for FOLD is 251.96M, and at present, short sellers hold a 8.55% of that float. The average trading volume of FOLD on May 25, 2023 was 2.48M shares.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


FOLD) stock’s latest price update

Amicus Therapeutics Inc. (NASDAQ: FOLD)’s stock price has decreased by -0.34 compared to its previous closing price of 11.75. However, the company has seen a 5.12% increase in its stock price over the last five trading sessions.

FOLD’s Market Performance

FOLD’s stock has risen by 5.12% in the past week, with a monthly rise of 1.39% and a quarterly drop of -10.20%. The volatility ratio for the week is 4.36% while the volatility levels for the last 30 days are 4.23% for Amicus Therapeutics Inc. The simple moving average for the past 20 days is 0.54% for FOLD’s stock, with a 0.43% simple moving average for the past 200 days.

FOLD Trading at 2.24% from the 50-Day Moving Average

After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.39% of loss for the given period.

Volatility was left at 4.23%, however, over the last 30 days, the volatility rate increased by 4.36%, as shares surge +1.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.91% upper at present.

During the last 5 trading sessions, FOLD rose by +5.12%, which changed the moving average for the period of 200-days by -6.62% in comparison to the 20-day moving average, which settled at $11.65. In addition, Amicus Therapeutics Inc. saw -4.10% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at FOLD starting from Crowley John F, who sale 6,044 shares at the price of $11.18 back on May 15. After this action, Crowley John F now owns 962,361 shares of Amicus Therapeutics Inc., valued at $67,577 using the latest closing price.

Campbell Bradley L, the President & CEO of Amicus Therapeutics Inc., sale 11,700 shares at $11.80 during a trade that took place back on May 01, which means that Campbell Bradley L is holding 823,454 shares at $138,093 based on the most recent closing price.

Stock Fundamentals for FOLD

Current profitability levels for the company are sitting at:

  • -62.09 for the present operating margin
  • +86.65 for the gross margin

The net margin for Amicus Therapeutics Inc. stands at -71.85. The total capital return value is set at -30.91, while invested capital returns managed to touch -36.21. Equity return is now at value -153.70, with -27.40 for asset returns.

Based on Amicus Therapeutics Inc. (FOLD), the company’s capital structure generated 367.44 points at debt to equity in total, while total debt to capital is 78.61. Total debt to assets is 62.43, with long-term debt to equity ratio resting at 360.49. Finally, the long-term debt to capital ratio is 77.12.

When we switch over and look at the enterprise to sales, we see a ratio of 10.40, with the company’s debt to enterprise value settled at 0.12. The receivables turnover for the company is 5.54 and the total asset turnover is 0.40. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.05.


In summary, Amicus Therapeutics Inc. (FOLD) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.